ppat.1009257.g005.tif (620.41 kB)
Mapping of mAb neutralizing activity.
figure
posted on 2021-02-08, 19:17 authored by Tysheena P. Charles, Samantha L. Burton, Prabhu S. Arunachalam, Christopher A. Cottrell, Leigh M. Sewall, Venkata S. Bollimpelli, Sailaja Gangadhara, Antu K. Dey, Andrew B. Ward, George M. Shaw, Eric Hunter, Rama R. Amara, Bali Pulendran, Marit J. van Gils, Cynthia A. DerdeynNeutralizing activity against the parental BG505 and mutant PVs was evaluated using the TZM-bl assay in (A—F). The mAb is indicated above each graph, which displays percent infectivity plotted against mAb concentration in μg/ml. mAbs VRC01 (E) and EM4C04 (F) were used as positive and negative controls, respectively. (G) The log10 fold increase or decrease in IC50 titer of each mutant PV relative to the parental BG505 PV is shown. An increase in IC50 of greater than 0.5log10 is highlighted red.
History
Usage metrics
Keywords
BG 505 SOSIP immunizationserum neutralization titerserum nAb titersBG 505 SOSIP .664.T gp 140RMBG 505 Env pseudovirusneutralizing mAb familytier 2 autologous neutralizing antibodyPVmucosal SHIV infection Stabilized HIVN 611-shielded epitopes465 glycan holeELISAautologous intra-vaginal simian-hum...BG 505 SOSIPglycan holeBG 505 HIV
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC